IBA selected by MD Anderson Cancer Center to supply three Proteus®ONE systems

Core Insights - IBA has signed a contract with the University of Texas MD Anderson Cancer Center to modernize its Proton Therapy Center in Houston with three ProteusONE systems, enhancing cancer treatment capabilities [1][2][3] Company Overview - IBA (Ion Beam Applications S.A.) is a leader in particle accelerator technology and proton therapy solutions, employing approximately 2,000 people globally [5] - The company is listed on the EURONEXT stock exchange and is recognized as a certified B Corporation, meeting high social and environmental performance standards [5][6] Contract Details - The project was awarded to IBA through a competitive RFP process, and the typical price for one ProteusONE solution, including maintenance, ranges from USD 45 to 55 million [2][10] - This contract will be recorded in IBA's 2025 order intake, with the first installment triggering the announcement of the commercial contract [10] Technological Impact - The ProteusONE systems are designed to integrate future innovations, supporting improved patient care and advanced research activities [3] - MD Anderson's recent clinical trial results position proton therapy as a new standard of care for advanced oropharyngeal cancer, highlighting the effectiveness of IBA's technology [3][11] Industry Context - MD Anderson Cancer Center is ranked 1 in cancer care by U.S. News & World Report and is a leading institution in cancer research and treatment [1][8] - The collaboration aligns with both organizations' missions to advance cancer treatment and improve patient outcomes [3][6]